Lyfjastofnun

Lyfjastofnun, the Icelandic Medicines Agency, plays a crucial role in ensuring the safety and efficacy of pharmaceuticals and medical devices for patients and the general public. Responsible for the regulation of both prescription and over-the-counter medications, Lyfjastofnun oversees the market authorizations of over 2,920 drugs, ensuring they meet stringent quality standards. The agency also provides guidance on drug safety, monitors adverse drug reactions, and facilitates clinical trials to gather essential data on new medications.

In addition to drug regulation, Lyfjastofnun manages the licensing process for pharmacies and wholesalers, establishing a framework for quality control across all dispensaries in Iceland. The agency offers educational resources for healthcare professionals and consumers regarding drug interactions and side effects. With a focus on transparency and public health, Lyfjastofnun is dedicated to advancing effective medication practices and ensuring consistent availability of essential drugs, particularly amidst ongoing health crises like COVID-19. Through its robust regulatory framework, Lyfjastofnun fosters innovation while prioritizing patient safety.